TY - JOUR
T1 - Antioxidant activity and cellular uptake of the hydroxamate-based fungal iron chelators pyridoxatin, desferriastechrome and desferricoprogen
AU - da Silva, Gabriel Souto
AU - Shang, Zhuo
AU - Kalansuriya, Pabasara
AU - Capon, Robert J.
AU - Espósito, Breno Pannia
PY - 2019/8/1
Y1 - 2019/8/1
N2 - The hydroxamate class of compounds is well known for its pharmacological applications, especially in the context of chelation therapy. In this work we investigate the performance of the fungal hydroxamates pyridoxatin (PYR), desferriastechrome (DAC) and desferricoprogen (DCO) as mitigators of stress caused by iron overload (IO) both in buffered medium and in cells. Desferrioxamine (DFO), the gold standard for IO treatment, was used as comparison. It was observed that all the fungal chelators (in aqueous medium) or PYR and DAC (in cells) are powerful iron scavengers. However only PYR and DCO (in aqueous medium) or PYR (in cells) were also antioxidant against two forms of iron-dependent oxidative stress (ascorbate or peroxide oxidation). These findings reveal that PYR is an interesting alternative to DFO for iron chelation therapy, since it has the advantage of being cell permeable and thus potentially orally active.
AB - The hydroxamate class of compounds is well known for its pharmacological applications, especially in the context of chelation therapy. In this work we investigate the performance of the fungal hydroxamates pyridoxatin (PYR), desferriastechrome (DAC) and desferricoprogen (DCO) as mitigators of stress caused by iron overload (IO) both in buffered medium and in cells. Desferrioxamine (DFO), the gold standard for IO treatment, was used as comparison. It was observed that all the fungal chelators (in aqueous medium) or PYR and DAC (in cells) are powerful iron scavengers. However only PYR and DCO (in aqueous medium) or PYR (in cells) were also antioxidant against two forms of iron-dependent oxidative stress (ascorbate or peroxide oxidation). These findings reveal that PYR is an interesting alternative to DFO for iron chelation therapy, since it has the advantage of being cell permeable and thus potentially orally active.
KW - Desferriastechrome
KW - Desferricoprogen
KW - Iron
KW - Overload
KW - Pyridoxatin
UR - http://www.scopus.com/inward/record.url?scp=85066792142&partnerID=8YFLogxK
U2 - 10.1007/s10534-019-00202-7
DO - 10.1007/s10534-019-00202-7
M3 - Article
C2 - 31152280
AN - SCOPUS:85066792142
SN - 0966-0844
VL - 32
SP - 707
EP - 715
JO - Biometals
JF - Biometals
IS - 4
ER -